Erythropoietic Protoporphyria Epp clinical trials

Explore recruiting erythropoietic protoporphyria epp clinical trials.

Recruiting erythropoietic protoporphyria epp studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Erythropoietic Protoporphyria Epp trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Study to Evaluate the Pharmacokinetics of Afamelanotide in Patients with Erythropoietic Protoporphyria (EPP).

Belgium, Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

MT-7117-A-302 Study: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X-Linked Protoporphyria

Spain, Bulgaria, Netherlands, France, Czechia, Poland +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy, Safety, and Tolerability in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

Germany, Ireland, Spain, France, Norway, Netherlands +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

Norway, Sweden, Italy, Spain, Germany, Bulgaria +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

HELIOS: An Open-Label, Long-Term Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP).

Italy, France, Ireland, Belgium, Sweden, Germany +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Erythropoietic Protoporphyria Epp trials by city

Erythropoietic Protoporphyria Epp in Toronto Erythropoietic Protoporphyria Epp in Vancouver Erythropoietic Protoporphyria Epp in Montreal Erythropoietic Protoporphyria Epp in Calgary Erythropoietic Protoporphyria Epp in Edmonton Erythropoietic Protoporphyria Epp in Ottawa Erythropoietic Protoporphyria Epp in Winnipeg Erythropoietic Protoporphyria Epp in Quebec City Erythropoietic Protoporphyria Epp in Hamilton Erythropoietic Protoporphyria Epp in Kitchener Erythropoietic Protoporphyria Epp in London Erythropoietic Protoporphyria Epp in Halifax Erythropoietic Protoporphyria Epp in New York Erythropoietic Protoporphyria Epp in Los Angeles Erythropoietic Protoporphyria Epp in Chicago Erythropoietic Protoporphyria Epp in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease